TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19293593

Group type: EXPERIMENTAL
Intervention: RET‐Y measurement in patients with absolute iron deficiency
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: RET‐Y measurement in patients with functional iron deficiency
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: RET‐Y measurement in EPO‐independent patients
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: RET‐Y levels comparison to normal population
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Correlation analysis of RET‐Y levels
Number of subjects: 289
Study: 17412546

Group type: EXPERIMENTAL
Intervention: 0.05mmol/kg gadodiamide
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: 0.1mmol/kg gadodiamide
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: 0.2mmol/kg gadodiamide
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: 0.01mmol/kg gadodiamide
Number of subjects: 273

Group type: COMPARATOR
Intervention: All doses compared to 0.01mmol/kg
Number of subjects: 273
Study: 14769684

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens (0.625 mg) with medroxyprogesterone acetate (2.5 mg)
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 11124753

Group type: EXPERIMENTAL
Intervention: Lithium-tagged yogurt (500 mL) for 6 weeks
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lithium supplement (250 micromol/d) for 13 days
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Half the dose (125 micromol lithium/d) taken on each of 2 days
Number of subjects: 90
Study: 9188873

Group type: EXPERIMENTAL
Intervention: EMLA® cream
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: EMLA® patch
Number of subjects: 12
Study: 8453559

Group type: EXPERIMENTAL
Intervention: Subcutaneous recombinant interferon alfa‐2a and IL‐2 at a dose of 7.5 million units (MU)/m2 of interferon alfa‐2a and 1.5 MU/m2 of IL‐2, administered three and five times weekly for 4 weeks
Number of subjects: 33
Study: 2943106

Group type: EXPERIMENTAL
Intervention: Normal luteal phase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normal follicular phase
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hyperandrogenism
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (150 mg trimestrially)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Ethinyl-oestradiol (1 mg daily for 5 days)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Days +4 to +9 of menstrual cycle (luteal phase)
Number of subjects: 28
Study: 29337026

Group type: EXPERIMENTAL
Intervention: rhGH 4 mg group
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: rhGH 8 mg group
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 27072941

Group type: EXPERIMENTAL
Intervention: 38‐h communication skills training program for multidisciplinary radiotherapy teams
Number of subjects: 198

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 198
Study: 24470256

Group type: EXPERIMENTAL
Intervention: Tactile cue presented to the left or right hand with hands aligned with inner visual target locations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tactile cue presented to the left or right hand with hands aligned with outer visual target locations.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unseen posture changes with inner and outer target eccentricities of 10º and 86º.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hands completely covered during the experiment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hands in view during the experiment.
Number of subjects: 0
Study: 22353915

Group type: EXPERIMENTAL
Intervention: Education group (Group II) - guardians received a pamphlet about how to help a child cooperate with the dentist during dental treatment.
Number of subjects: 235

Group type: COMPARATOR
Intervention: Control group (Group I) - guardians received a pamphlet about how to clean children's teeth.
Number of subjects: 235
Study: 20198451

Group type: COMPARATOR
Intervention: 15 ml/kg total body weight (TBW) of IV crystalloid solution (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 40 ml/kg total body weight (TBW) of IV crystalloid solution (Group B)
Number of subjects: 100
Study: 18668692

Group type: EXPERIMENTAL
Intervention: Single dose of dexamethasone (1 mg/kg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Multiple doses of dexamethasone (0.15 mg/kg for 4 days)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Single dose of dexamethasone
Number of subjects: 125

Group type: COMPARATOR
Intervention: Multiple doses of dexamethasone
Number of subjects: 125
Study: 15982131

Group type: EXPERIMENTAL
Intervention: 3-D relatable displays
Number of subjects: 0

Group type: COMPARATOR
Intervention: 3-D nonrelatable displays
Number of subjects: 0
Study: 12584784

Group type: EXPERIMENTAL
Intervention: Jiangqian granule (JQG)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Ritalin (Control)
Number of subjects: 80
Study: 10614835

Group type: EXPERIMENTAL
Intervention: Vitamin C (initial dose of 2.0 g followed by a constant infusion at 20 mg/min)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Primary PTCA without vitamin C
Number of subjects: 27

Group type: COMPARATOR
Intervention: Elective PTCA in stable effort angina (Control Group)
Number of subjects: 27
Study: 7627244

Group type: EXPERIMENTAL
Intervention: Orlistat 30 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Orlistat 180 mg/day
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Orlistat 360 mg/day
Number of subjects: 188

Group type: COMPARATOR
Intervention: Diet alone (Placebo)
Number of subjects: 188
Study: 1512604

Group type: EXPERIMENTAL
Intervention: Low-dose acetylsalicylic acid (50 mg daily) and dipyridamole (400 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 6390998

Group type: EXPERIMENTAL
Intervention: Low-dose heparin in combination with dihydroergotamine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-dose heparin alone
Number of subjects: 200
Study: 30328246

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 100 mg/day for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29981086

Group type: EXPERIMENTAL
Intervention: 4 home visits with a health educator, emails, and mailed incentives (4HV)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2 home visits with a health educator, emails, and mailed incentives (2HV)
Number of subjects: 44

Group type: COMPARATOR
Intervention: General health advice through emails (control)
Number of subjects: 44
Study: 26207956

Group type: EXPERIMENTAL
Intervention: 3D video training
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2D video training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional tactic board training
Number of subjects: 0
Study: 24434503

Group type: EXPERIMENTAL
Intervention: Samatasvir 25-100mg per day for 3 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 22278874

Group type: EXPERIMENTAL
Intervention: Antistick phospholipid solution (Electro Lube)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no antistick solution)
Number of subjects: 61
Study: 21084043

Group type: EXPERIMENTAL
Intervention: Contiflo ICON 400 µg tablets
Number of subjects: 32

Group type: COMPARATOR
Intervention: Flomaxtra XL 400 µg tablets
Number of subjects: 32
Study: 18540781

Group type: EXPERIMENTAL
Intervention: Olanzapine 2.5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Olanzapine 5.0 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15906662

Group type: EXPERIMENTAL
Intervention: Amphotericin B (0.7 mg/kg/d) plus rifampin (600 mg/d) for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amphotericin B (0.7 mg/kg/d) alone for 2 weeks followed by fluconazole (400 mg/d) for 8 weeks
Number of subjects: 40
Study: 12571861

Group type: COMPARATOR
Intervention: Sulfasalazine (placebo-controlled study)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Radiologic scoring method
Number of subjects: 67
Study: 10558970

Group type: EXPERIMENTAL
Intervention: Partially enteric‐coated preparation of bovine immunoglobulins
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8549868

Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cilazapril and Amlodipine
Number of subjects: 44
Study: 1846057

Group type: EXPERIMENTAL
Intervention: lisinopril (10 to 40 mg)
Number of subjects: 144

Group type: COMPARATOR
Intervention: atenolol (50 to 100 mg)
Number of subjects: 144
Study: 6354602

Group type: EXPERIMENTAL
Intervention: Ciramadol (60 or 30 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Codeine (60 mg)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31837947

Group type: EXPERIMENTAL
Intervention: Low-volume high-intensity interval training (LV-HIIT)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise training (MICET)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study: 30744672

Group type: EXPERIMENTAL
Intervention: Sensory Integration Therapy (SIT)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 216
Study: 28527421

Group type: EXPERIMENTAL
Intervention: Lofexidine HCl 3.2mg daily in four divided doses
Number of subjects: 264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 264
Study: 26400476

Group type: EXPERIMENTAL
Intervention: Silymarin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 24090266

Group type: EXPERIMENTAL
Intervention: 8 mg of ramelteon (melatonin agonist)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 22461887

Group type: EXPERIMENTAL
Intervention: Sitting in a 'straight' position
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sitting in a 'bent' position
Number of subjects: 25
Study: 19623858

Group type: EXPERIMENTAL
Intervention: Lyman NTCP model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Critical volume NTCP model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Relative seriality NTCP model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean Lung Dose (MLD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung volumes irradiated at 10Gy (V10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lung volumes irradiated at 20Gy (V20)
Number of subjects: 0
Study: 17298463

Group type: EXPERIMENTAL
Intervention: Bronchial washing before forceps biopsy (pre-biopsy)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Bronchial washing after forceps biopsy (post-biopsy)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Bronchial washing (both groups)
Number of subjects: 207
Study: 15086698

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard urticaria therapies (corticosteroids, H2-antihistamines, H1-antihistamines, doxepin)
Number of subjects: 21
Study: 11895352

Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: No nerve conduction studies
Number of subjects: 0
Study: 9793619

Group type: EXPERIMENTAL
Intervention: MDPI (100 micrograms of salbutamol)
Number of subjects: 36

Group type: COMPARATOR
Intervention: pMDI + S (100 micrograms of salbutamol)
Number of subjects: 36
Study: 7714461

Group type: EXPERIMENTAL
Intervention: Folic acid (2.5 or 10 mg daily for 6 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 68
Study: 1955055

Group type: EXPERIMENTAL
Intervention: Early trabeculectomy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 104
Study: 7009090

Group type: EXPERIMENTAL
Intervention: Transparent adhesive drape
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional dressing
Number of subjects: 90
Study: 31290481

Group type: EXPERIMENTAL
Intervention: ANIN RS I (risk score for all-cause mortality)
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: ANIN RS II (risk score for cardiovascular mortality)
Number of subjects: 1064
Study: 27937064

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via MDPI 50, 100, 200, or 400 mcg twice daily for 12 weeks
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via MDPI
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via MDPI and Fp DPI
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Fp) delivered via DPI 250 mcg
Number of subjects: 640

Group type: COMPARATOR
Intervention: Placebo MDPI
Number of subjects: 640
Study: 25605838

Group type: EXPERIMENTAL
Intervention: Lapatinib-capecitabine
Number of subjects: 540

Group type: COMPARATOR
Intervention: Trastuzumab-capecitabine
Number of subjects: 540
Study: 24923372

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thiopentone sodium (5 mg/kg)
Number of subjects: 60
Study: 22550143

Group type: EXPERIMENTAL
Intervention: Traditional public service announcement (PSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative fact appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive fact appeal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Information sources
Number of subjects: 0
Study: 19490551

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 8221

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 8221

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 8221
Study: 17131169

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin (both doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0
Study: 15213046

Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1669
Study: 11603453

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (10 mg/kg) 4 hours preoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no steroid administration)
Number of subjects: 50
Study: 9847641

Group type: EXPERIMENTAL
Intervention: 0.5% tetracaine drops and intravenous fentanyl and propofol with continuous sedation (Group I)
Number of subjects: 260

Group type: COMPARATOR
Intervention: 2% lidocaine in the retrobulbar space and hypnotic doses of intravenous propofol (Group II)
Number of subjects: 260
Study: 8079969

Group type: EXPERIMENTAL
Intervention: Cuprophane hemodialysis
Number of subjects: 10

Group type: COMPARATOR
Intervention: Polyamide hemodialysis (control)
Number of subjects: 10
Study: 2634902

Group type: EXPERIMENTAL
Intervention: Verapamil (120 mg twice daily)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metoclopramide (10 mg i.v.)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 712981

Group type: EXPERIMENTAL
Intervention: Megavitamin combination
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 29843843

Group type: EXPERIMENTAL
Intervention: 12.0 cm/hen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 9.5 cm/hen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 8.5 cm/hen
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 6.5 cm/hen
Number of subjects: 60
Study: 28622634

Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Recombinant FSH
Number of subjects: 90
Study: 25684006

Group type: COMPARATOR
Intervention: Fentanyl group (0.5% hyperbaric bupivacaine 0.2 mL + fentanyl 20 μg + 5% dextrose 1.4 mL)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sufentanil group (0.5% hyperbaric bupivacaine 0.2 mL + sufentanil 5 μg + 5% dextrose 1.7 mL)
Number of subjects: 56
Study: 23764624

Group type: EXPERIMENTAL
Intervention: Experimental PrEP regimens (specifics not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: FTC/TDF (emtricitabine/tenofovir)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New PrEP product with potential for higher adherence and potency (specifics not provided)
Number of subjects: 0
Study: 19933540

Group type: EXPERIMENTAL
Intervention: Meds‐Help (pharmacy-based intervention)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 118
Study: 19761135

Group type: EXPERIMENTAL
Intervention: 1000 kcal/d immun‐enhancing enteral nutrition (IEN)
Number of subjects: 50

Group type: COMPARATOR
Intervention: 1000 kcal/d standard enteral nutrition
Number of subjects: 50
Study: 17931382

Group type: EXPERIMENTAL
Intervention: BNP plasma levels low (< 100 pg mL(‐1))
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BNP plasma levels intermediate (100-500 pg mL(‐1))
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BNP plasma levels high (> 500 pg mL(‐1))
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BNP concentration
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BNP plasma levels in non-cardiac causes
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: BNP plasma levels in cardiac causes
Number of subjects: 452
Study: 15230644

Group type: EXPERIMENTAL
Intervention: Tegaserod 6mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 0
Study: 11700404

Group type: EXPERIMENTAL
Intervention: Ulinastatin 300,000 units
Number of subjects: 48

Group type: COMPARATOR
Intervention: Blood transfusion
Number of subjects: 48
Study: 9219678

Group type: EXPERIMENTAL
Intervention: Hyalgan (500-730 kDa molecular weight), three cycles of three intra-articular injections (once a week during 2 weeks) every 3 months
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (conventional therapy)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Hyalgan
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study: 8424294

Group type: EXPERIMENTAL
Intervention: Metoclopramide (1 mg.kg‐1 i.v. preoperatively, followed by 1.5 mg.kg‐1 infusion over 9 h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (corresponding volumes of solvent)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 3631499

Group type: EXPERIMENTAL
Intervention: Computer program for calculating allowable blood loss
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard method using blood volume estimated on a volume per weight basis
Number of subjects: 80
Study: 31631741

Group type: EXPERIMENTAL
Intervention: Age 8 years
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ages 8 to 12 years
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Teasing and prosocial lies interpretation
Number of subjects: 124
Study: 29614243

Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion (halobetasol propionate 0.01% plus tazarotene 0.045%)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: HP/TAZ lotion
Number of subjects: 418

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 418
Study: 27037169

Group type: COMPARATOR
Intervention: 10 mL 2% Carbocaine lidocaine gel with 1 mL 0.9% saline (group 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 mL 5% NaHCO3 solution (group 2)
Number of subjects: 0
Study: 24997651

Group type: EXPERIMENTAL
Intervention: 1 g dose of tranexamic acid (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 20 mg/kg dose of tranexamic acid (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (25 patients)
Number of subjects: 60
Study: 22040403

Group type: EXPERIMENTAL
Intervention: Prosthodontic stent with 3D imaging (study group)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no stent, conventional techniques)
Number of subjects: 41
Study: 20552368

Group type: EXPERIMENTAL
Intervention: Open tension-free mesh-plug hernia technique
Number of subjects: 164

Group type: COMPARATOR
Intervention: Transabdominal preperitoneal (TAPP) technique
Number of subjects: 164

Group type: COMPARATOR
Intervention: Totally extraperitoneal (TEP) technique
Number of subjects: 164
Study: 18211278

Group type: EXPERIMENTAL
Intervention: Individualized mental health consultation focused on behaviorally-based strategies for decreasing disruptive behaviors
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Individualized mental health consultation
Number of subjects: 96

Group type: COMPARATOR
Intervention: Assessment/attention comparison group with typical treatment available
Number of subjects: 96
Study: 16797163

Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 12949850

Group type: EXPERIMENTAL
Intervention: Risperidone 1 to 3 mg/day
Number of subjects: 176

Group type: COMPARATOR
Intervention: Olanzapine 5 to 20 mg/day
Number of subjects: 176
Study: 10966692

Group type: COMPARATOR
Intervention: Placebo (group A)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oral temazepam (group B)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (group C)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Intravenous midazolam and fentanyl (group D)
Number of subjects: 125
Study: 8990802

Group type: EXPERIMENTAL
Intervention: 1.5 g of calcium/day for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 1389813

Group type: COMPARATOR
Intervention: Isoflurane at 0.0 MAC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.1 MAC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.2 MAC
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Isoflurane at 0.4 MAC
Number of subjects: 8